DK1121099T3 - I maven hvilende farmaceutiske præparater til kontrolleret frigivelse - Google Patents

I maven hvilende farmaceutiske præparater til kontrolleret frigivelse

Info

Publication number
DK1121099T3
DK1121099T3 DK99947537T DK99947537T DK1121099T3 DK 1121099 T3 DK1121099 T3 DK 1121099T3 DK 99947537 T DK99947537 T DK 99947537T DK 99947537 T DK99947537 T DK 99947537T DK 1121099 T3 DK1121099 T3 DK 1121099T3
Authority
DK
Denmark
Prior art keywords
controlled
stomach
pharmaceutical preparations
release pharmaceutical
release
Prior art date
Application number
DK99947537T
Other languages
English (en)
Inventor
Gerard Alaux
Frederic Andre
Alain Cuine
Gareth Lewis
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK1121099T3 publication Critical patent/DK1121099T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99947537T 1998-10-16 1999-10-12 I maven hvilende farmaceutiske præparater til kontrolleret frigivelse DK1121099T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9812977A FR2784583B1 (fr) 1998-10-16 1998-10-16 Composition pharmaceutique a residence gastrique et a liberation controlee
PCT/FR1999/002443 WO2000023045A1 (fr) 1998-10-16 1999-10-12 Composition pharmaceutique a residence gastrique et a liberation controlee

Publications (1)

Publication Number Publication Date
DK1121099T3 true DK1121099T3 (da) 2004-08-09

Family

ID=9531635

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99947537T DK1121099T3 (da) 1998-10-16 1999-10-12 I maven hvilende farmaceutiske præparater til kontrolleret frigivelse

Country Status (12)

Country Link
US (1) US6861072B1 (da)
EP (1) EP1121099B1 (da)
JP (1) JP2002527464A (da)
AT (1) ATE264666T1 (da)
AU (1) AU774723B2 (da)
CA (1) CA2347105C (da)
DE (1) DE69916640T2 (da)
DK (1) DK1121099T3 (da)
ES (1) ES2219062T3 (da)
FR (1) FR2784583B1 (da)
PT (1) PT1121099E (da)
WO (1) WO2000023045A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
MXPA03012041A (es) 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
ES2247897B1 (es) * 2003-12-18 2007-05-01 Gat Formulation Gmbh Tabletas con matriz polimerica emulsionada para emision controlada de gases y procedimiento para su fabricacion.
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
WO2007048223A2 (en) * 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
US20110112383A1 (en) * 2005-11-08 2011-05-12 Plensat, Inc Devices, systems and methods for treatment of eating disorders
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US7879355B2 (en) * 2005-11-08 2011-02-01 Plensat Llc Method and system for treatment of eating disorders
US8206742B2 (en) * 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
SI2007362T1 (sl) 2006-04-04 2018-12-31 Kg Acquisition Llc Peroralne odmerne oblike, ki vključujejo antitrombocitno sredstvo in inhibitor kisline
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
DE102007026037A1 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
EP2329810A4 (en) 2008-08-18 2012-09-19 Team Academy Of Pharmaceutical Science DRUG DISPENSING SYSTEM WITH MAGNETIC RETENTION, MANUFACTURING PROCESS AND APPLICATION
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
KR101137466B1 (ko) * 2009-06-12 2012-04-20 안국약품 주식회사 염산 알푸조신 함유 서방성 정제
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2967352B1 (fr) * 2010-11-12 2012-12-28 Unither Dev Comprime effervescent pour l'administration par voie orale de principes actifs
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN116942623B (zh) * 2023-08-29 2025-09-02 津药达仁堂集团股份有限公司新新制药厂 一种盐酸硫必利片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
WO1996029054A1 (en) * 1995-03-17 1996-09-26 The Boots Company Plc Pectin pharmaceutical compositions
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
NZ334018A (en) * 1996-08-29 1999-06-29 Synthelabo Multilayered controlled release tablet comprising a layer of alfuzosin hydrochloride and at least one layer of hydrophillic polymers
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica

Also Published As

Publication number Publication date
DE69916640T2 (de) 2005-03-31
CA2347105A1 (en) 2000-04-27
US6861072B1 (en) 2005-03-01
CA2347105C (en) 2009-09-29
AU774723B2 (en) 2004-07-08
ES2219062T3 (es) 2004-11-16
EP1121099A1 (fr) 2001-08-08
ATE264666T1 (de) 2004-05-15
JP2002527464A (ja) 2002-08-27
AU6094799A (en) 2000-05-08
FR2784583B1 (fr) 2002-01-25
FR2784583A1 (fr) 2000-04-21
EP1121099B1 (fr) 2004-04-21
DE69916640D1 (de) 2004-05-27
WO2000023045A1 (fr) 2000-04-27
PT1121099E (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
DK1121099T3 (da) I maven hvilende farmaceutiske præparater til kontrolleret frigivelse
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
PL370793A1 (en) Gastric retention controlled drug delivery system
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
ATE232100T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
NO984703L (no) Tabletter med farmas°ytisk kontrollert frigj°ring, som inneholder en bµrer basert pÕ tverrbundet amylose og hydroksypropylmetylcellulose
DK0527942T3 (da) System til frigivelse af et lægemiddel i tyktarmen
ATE304366T1 (de) Lactobacillus casei rhamnosus-haltige pharmazeutische formulierung
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
ATE300286T1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
NO20020572L (no) Flytende farmasöytisk sammensetning som omfatter en aktiv fase og en ikke-aktiv fase
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
AR015586A1 (es) Composicion farmaceutica de residencia gastrica.
ATE187890T1 (de) Ligandgerichtete enzyme-prodrug therapie
ATE213933T1 (de) Orale zubereitung, enthaltend in einer in wässrigem medium quellbaren matrix wenigstens einen pharmazeutischen wirkstoff
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
DK0615444T3 (da) Peroral indgivelsesform til peptidlægemidler, især insulin
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
AU1287001A (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
DE3772954D1 (de) Arzneimittel mit verzoegerter wirkstoffabgabe.
UA10108A (uk) Дитячий лікарський засіб "паравіт", який виявляє жарознижуючу та анальгетичну дію
UA39418A (uk) Спосіб лікування виразкової хвороби, асоційованої з helicobacter pylori